185 related articles for article (PubMed ID: 26259553)
1. Chemical chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in fibroblasts.
Hossain MA; Higaki K; Shinpo M; Nanba E; Suzuki Y; Ozono K; Sakai N
Brain Dev; 2016 Feb; 38(2):175-80. PubMed ID: 26259553
[TBL] [Abstract][Full Text] [Related]
2. Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency.
Higaki K; Li L; Bahrudin U; Okuzawa S; Takamuram A; Yamamoto K; Adachi K; Paraguison RC; Takai T; Ikehata H; Tominaga L; Hisatome I; Iida M; Ogawa S; Matsuda J; Ninomiya H; Sakakibara Y; Ohno K; Suzuki Y; Nanba E
Hum Mutat; 2011 Jul; 32(7):843-52. PubMed ID: 21520340
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast screening for chaperone therapy in beta-galactosidosis.
Iwasaki H; Watanabe H; Iida M; Ogawa S; Tabe M; Higaki K; Nanba E; Suzuki Y
Brain Dev; 2006 Sep; 28(8):482-6. PubMed ID: 16617000
[TBL] [Abstract][Full Text] [Related]
4. Chemical chaperone therapy: luciferase assay for screening of β-galactosidase mutations.
Li L; Higaki K; Ninomiya H; Luan Z; Iida M; Ogawa S; Suzuki Y; Ohno K; Nanba E
Mol Genet Metab; 2010 Dec; 101(4):364-9. PubMed ID: 20826101
[TBL] [Abstract][Full Text] [Related]
5. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
Suzuki Y
Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
[TBL] [Abstract][Full Text] [Related]
6. Beta-galactosidase deficiency: an approach to chaperone therapy.
Suzuki Y
J Inherit Metab Dis; 2006; 29(2-3):471-6. PubMed ID: 16763919
[TBL] [Abstract][Full Text] [Related]
7. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.
Matsuda J; Suzuki O; Oshima A; Yamamoto Y; Noguchi A; Takimoto K; Itoh M; Matsuzaki Y; Yasuda Y; Ogawa S; Sakata Y; Nanba E; Higaki K; Ogawa Y; Tominaga L; Ohno K; Iwasaki H; Watanabe H; Brady RO; Suzuki Y
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15912-7. PubMed ID: 14676316
[TBL] [Abstract][Full Text] [Related]
8. The pharmacological chaperone N-n-butyl-deoxygalactonojirimycin enhances β-galactosidase processing and activity in fibroblasts of a patient with infantile GM1-gangliosidosis.
Mohamed FE; Al Sorkhy M; Ghattas MA; Al-Gazali L; Al-Dirbashi O; Al-Jasmi F; Ali BR
Hum Genet; 2020 May; 139(5):657-673. PubMed ID: 32219518
[TBL] [Abstract][Full Text] [Related]
9. The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.
Caciotti A; Donati MA; d'Azzo A; Salvioli R; Guerrini R; Zammarchi E; Morrone A
Eur J Paediatr Neurol; 2009 Mar; 13(2):160-4. PubMed ID: 18571950
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of the beta-galactosidase-carboxypeptidase complex in GM1-gangliosidosis and beta-galactosialidosis fibroblasts.
D'Agrosa RM; Hubbes M; Zhang S; Shankaran R; Callahan JW
Biochem J; 1992 Aug; 285 ( Pt 3)(Pt 3):833-8. PubMed ID: 1497621
[TBL] [Abstract][Full Text] [Related]
11. Chemical chaperone therapy for GM1-gangliosidosis.
Suzuki Y
Cell Mol Life Sci; 2008 Feb; 65(3):351-3. PubMed ID: 18202827
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic chaperone effect of N-octyl 4-epi-β-valienamine on murine G(M1)-gangliosidosis.
Suzuki Y; Ichinomiya S; Kurosawa M; Matsuda J; Ogawa S; Iida M; Kubo T; Tabe M; Itoh M; Higaki K; Nanba E; Ohno K
Mol Genet Metab; 2012 May; 106(1):92-8. PubMed ID: 22436580
[TBL] [Abstract][Full Text] [Related]
13. Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations.
Hossain MA; Higaki K; Saito S; Ohno K; Sakuraba H; Nanba E; Suzuki Y; Ozono K; Sakai N
J Hum Genet; 2015 Sep; 60(9):539-45. PubMed ID: 26108143
[TBL] [Abstract][Full Text] [Related]
14. Early proteolytic cleavage with loss of a C-terminal fragment underlies altered processing of the beta-galactosidase precursor in galactosialidosis.
Okamura-Oho Y; Zhang S; Hilson W; Hinek A; Callahan JW
Biochem J; 1996 Feb; 313 ( Pt 3)(Pt 3):787-94. PubMed ID: 8611156
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
Condori J; Acosta W; Ayala J; Katta V; Flory A; Martin R; Radin J; Cramer CL; Radin DN
Mol Genet Metab; 2016 Feb; 117(2):199-209. PubMed ID: 26766614
[TBL] [Abstract][Full Text] [Related]
16. A Turkish case of galactosialidosis with a new homozygous mutation in CTSA gene.
Kartal A; Aydın K
Metab Brain Dis; 2017 Aug; 32(4):973-975. PubMed ID: 28555253
[TBL] [Abstract][Full Text] [Related]
17. Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosidosis is linked to deficiency in the 67-kD spliced variant of beta-galactosidase.
Hinek A; Zhang S; Smith AC; Callahan JW
Am J Hum Genet; 2000 Jul; 67(1):23-36. PubMed ID: 10841810
[TBL] [Abstract][Full Text] [Related]
18. Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.
Cadaoas J; Hu H; Boyle G; Gomero E; Mosca R; Jayashankar K; Machado M; Cullen S; Guzman B; van de Vlekkert D; Annunziata I; Vellard M; Kakkis E; Koppaka V; d'Azzo A
Mol Ther Methods Clin Dev; 2021 Mar; 20():191-203. PubMed ID: 33426146
[TBL] [Abstract][Full Text] [Related]
19. New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor.
Malvagia S; Morrone A; Caciotti A; Bardelli T; d'Azzo A; Ancora G; Zammarchi E; Donati MA
Mol Genet Metab; 2004 May; 82(1):48-55. PubMed ID: 15110321
[TBL] [Abstract][Full Text] [Related]
20. [Galactosialidosis: a new "de novo" mutation in CTSA gene in a patient with late infantile galactosialidosis].
García Hernández L; Sierra Sirvent J; Gort Mas L; Coll Roseli MJ
Arch Argent Pediatr; 2018 Feb; 116(1):e88-e92. PubMed ID: 29333829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
